Hepatitis Weekly

New hepatitis C virus study findings have been reported from J. Guitard et al

Hepatitis Weekly Library Library Home This article was published in Hepatitis Weekly, which you can subscribe to online.

"None received any HCV antiviral therapy. After the last intake of TAC, the patients underwent a 12-hour area under the curve (AUC(12)) measurement of both TAC and HCV viral loads. The next morning (D-0) patients were given CsA (4 mg/kg bid). At the first intake of CsA and at I month (M-1) later, the patients underwent AUC(12) for CsA and HCV viral loads. Biological data, including aspartate (AST) and alanine (ALT) aminotransferase, gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (AP), and bilirubin levels, were collected during AUC(12), and at M-1 and M-3. With respect to liver enzymes (AST, ALT, GGT), there was no significant difference between D-0, M-1, and M-3. Conversely, there was a significant decrease in AP between D-0 and M-3 (P = .02), and a significant increase in total bilirubin between Do and M-1 (P = .04), and between D-0 and M-3 (P = .01). HCV viral load significantly increased by M-3 (P = .01). At no time (D-0, M-1) was there any correlation between the AUC(12) of TAC or CsA, and between AUC(12) HCV viral load," wrote J. Guitard and colleagues.

The researchers concluded: "This pilot study found no acute or chronic anti-HCV effects from CsA that were evident within 12 hours after CsA administrations or beyond 1 month of CsA therapy, respectively."

Guitard and colleagues published the results of their research in Transplantation Proceedings (Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: A pilot study. Transplantation Proceedings, 2007;39(8):2603-2605).

For additional information, contact L. Rostaing, CHU Rangueil, Dept. of Nephrology, Avenue Jean Poulhes, TSA 50032, F-31059 Toulouse, France.

The publisher of the journal Transplantation Proceedings can be contacted at: Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010-1710, USA.

Keywords: France, Toulouse, Aminotransferase, Antiviral, Bioengineering, Biomedical Engineering, Biomedicine, Clinical Trial Research, Cyclosporine, Drugs, Enzyme Research, Gastroenterology, HCV, Hepatitis C Virus, Hepatology, Infectious Disease, Liver Transplant, Organ Transplant, Pharmaceuticals, Prednisone, Tacrolimus, Transpeptidase, Transplantation, Treatment, Viral Inhibition, Viral Load, Viral Therapy, Virology.

This article was prepared by Hepatitis Weekly editors from staff and other reports. Copyright 2008, Hepatitis Weekly via NewsRx.com.